Association of PNPLA3 polymorphism with hepatocellular carcinoma development and prognosis in viral and non-viral chronic liver diseases

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 18, 2016, Pages 8377-8382

  Khlaiphuengsin, Apichaya ^a   Kiatbumrung, Rattanaporn ^a   Payungporn, Sunchai ^a   Pinjaroen, Nutcha ^a   Tangkijvanich, Pisit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

ASH; HBV; HCC development; HCV; NASH; PNPLA3; Prognosis

Indexed keywords

ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

AGED; ALCOHOLIC FATTY LIVER; CANCER STAGING; CASE CONTROL STUDY; CHRONIC HEPATITIS; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FATTY LIVER, ALCOHOLIC; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS, CHRONIC; HUMANS; LIPASE; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84954306035     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.18.8377     Document Type: Article

References (35)

1. Brouwer WP, van der Meer AJ, Boonstra A, et al (2015). The impact of PNPLA3 (rs738409 C > G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver Int, 35, 438-47.
2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
3. Day CP (2006). From fat to inflammation. Gastroenterology, 130, 207-10.
4. Falleti E, Fabris C, Cmet S, et al (2011). PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int, 31, 1137-43.
5. Friedrich K, WannhoffA, Kattner S, et al (2014). PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. J Gastroenterol Hepatol, 29, 1477-84.
6. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
7. Guyot E, Sutton A, Rufat P, et al (2013). PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol, 58, 312-8.
8. He S, McPhaul C, Li JZ, et al (2010). A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem, 285, 6706-15.
9. Huang Y, He S, Li JZ, et al (2010). A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A, 107, 7892-7.
10. Jenkins CM, Mancuso DJ, Yan W, et al (2004). Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem, 279, 48968-75.
11. Jin F, Xiong WJ, Jing JC, et al (2011). Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol, 137, 1095-104.
12. Liu YL, Patman GL, Leathart JB, et al (2014). Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol, 61, 75-81.
13. Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711.
14. Nault JC (2014). Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol, 28, 937-47.
15. Nischalke HD, Berger C, Luda C, et al (2011). The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One, 6, 27087.
16. Patton HM, Patel K, Behling C, et al (2004). The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol, 40, 484-90.
17. Pingitore P, Pirazzi C, Mancina RM, et al (2014). Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta, 1841, 574-80.
18. Romeo S, Kozlitina J, Xing C, et al (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 40, 1461-5.
19. Rubbia-Brandt L, Quadri R, Abid K, et al (2000). Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol, 33, 106-15.
20. Salameh H, RaffE, Erwin A, et al (2015). PNPLA3 Gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. The American journal of gastroenterology, 110, 846-56.
21. Sato M, Kato N, Tateishi R, et al (2014). Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res, 44, 137-44.
22. Singal AG, Manjunath H, Yopp AC, et al (2014). The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. The American journal of gastroenterology, 109, 325-34.
23. Smagris E, BasuRay S, Li J, et al (2015). Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology, 61, 108-18.
24. Sookoian S, Castano GO, Burgueno AL, et al (2009). A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res, 50, 2111-6.
25. Sopipong W, Tangkijvanich P, Payungporn S, et al (2013). The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai patients. Asian Pac J Cancer Prev, 14, 2865-9.
26. Stickel F, Buch S, Lau K, et al (2011). Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology, 53, 86-95.
27. Takeuchi Y, Ikeda F, Moritou Y, et al (2013). The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol, 48, 405-12.
28. Tangkijvanich P, Hirsch P, Theamboonlers A, et al (1999). Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J Gastroenterol, 34, 227-33.
29. Trepo E, Guyot E, Ganne-Carrie N, et al (2012). PNPLA3 (rs738409 C > G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology, 55, 1307-8.
30. Trepo E, Nahon P, Bontempi G, et al (2014). Association between the PNPLA3 (rs738409 C > G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 59, 2170-7.
31. Trepo E, Pradat P, PotthoffA, et al (2011). Impact of patatinlike phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 54, 60-9.
32. Valenti L, Motta BM, Soardo G, et al (2013). PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. PLoS One, 8, 75982.
33. Vigano M, Valenti L, Lampertico P, et al (2013). Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 58, 1245-52.
34. Yuan X, Waterworth D, Perry JR, et al (2008). Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet, 83, 520-8.
35. Zampino R, Coppola N, Cirillo G, et al (2015). Patatin-Like Phospholipase Domain-Containing 3 I148M variant is associated with liver steatosis and fat distribution in Chronic Hepatitis B. Dig Dis Sci.